companies working on glp-1 drugs GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ glp-1 drugs pharmaceutical companies partnerships

Further studies are needed to investigate the bone impact of GLP-1Ra, dual- and triple-receptor agonists for GLP-1, glucose-dependent insulin releasing polypeptide (GIP), and glucagon in PwO

Estimates of cardiometabolic marker changes after treatment cessation are based on modeled projections of observed trends, with limited long-term follow-up

For those interested in the compound class and the underlying mechanisms, understanding the published evidence base now positions you to evaluate clinical options intelligently when they become available

Koehler, J

We thank Jordan Vinikoor for his assistance editing and revising this manuscript

July 1 is just around the corner so, hopefully, there will be more guidance coming soon.